Thanks for the link.
So sad that NASH can be avoided by lifestyle factors (diet & exercise). However, the market for a therapy is only increasing.
Amplia appears to be well positioned to be noticed as a candidate.
This announcement has come out of left field. I wasn't aware of the SMC Tokyo Lab work being in the pipeline. It goes to show that there is much happening behind the scenes as we await the Phase 2 trials.
I like the flow of information from the Board, and how they are focused on commercial outcomes.
Ann: ATX FAK Inhibitors Reduce Fibrosis in Animal Model of NASH, page-11
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
